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ABSTRACT
Head and neck squamous cell carcinomas (HNSCC) are an ideal immunotherapy 
target due to their high mutation burden and frequent infiltration with lymphocytes. 
Preclinical models to investigate targeted and combination therapies as well as 
defining biomarkers to guide treatment represent an important need in the field. 
Immunogenomics approaches have illuminated the role of mutation-derived tumor 
neoantigens as potential biomarkers of response to checkpoint blockade as well as 
representing therapeutic vaccines. Here, we aimed to define a platform for checkpoint 
and other immunotherapy studies using syngeneic HNSCC cell line models (MOC2 
and MOC22), and evaluated the association between mutation burden, predicted 
neoantigen landscape, infiltrating T cell populations and responsiveness of tumors to 
anti-PD1 therapy. We defined dramatic hematopoietic cell transcriptomic alterations 
in the MOC22 anti-PD1 responsive model in both tumor and draining lymph nodes. 
Using a cancer immunogenomics pipeline and validation with ELISPOT and tetramer 
analysis, we identified the H-2Kb-restricted ICAM1P315L (mICAM1) as a neoantigen in 
MOC22. Finally, we demonstrated that mICAM1 vaccination was able to protect against 
MOC22 tumor development defining mICAM1 as a bona fide neoantigen. Together 
these data define a pre-clinical HNSCC model system that provides a foundation for 
future investigations into combination and novel therapeutics.
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INTRODUCTION
Despite advances in surgical techniques, 
chemotherapeutics and targeted radiation therapy, 
oral cavity squamous cell carcinoma (OSCC) remains 
a treatment challenge and still carries a 60% 5-year 
survival rate [1]. Poor outcomes are due, at least in part, 
to the lack of robust sensitivity of OSCC to adjuvant 
therapies [2, 3]. To address this need for novel therapeutic 
modalities, significant efforts have been directed at better 
understanding the biology of these tumors to identify 
targeted treatment approaches. However, recent work 
to characterize the genomic landscape of head and neck 
squamous cell carcinomas (HNSCC) by the TCGA and 
others demonstrated that the majority of these tumors do 
not possess actionable mutations for targeted therapy [4]. 
In contrast to small molecule approaches, there has been 
significant interest in the role of immunotherapies in the 
treatment of HNSCC based largely on the success of these 
approaches in other carcinogen-induced cancer types [5, 
6]. Indeed, two published clinical trials, Keynote-012 and 
Checkmate-141, demonstrated clinical benefit with anti-
PD1 blocking monoclonal antibody (mAb) checkpoint 
inhibitors in patients with recurrent or metastatic HNSCC 
[7, 8]. The response rates to anti-PD1 mAbs in these 
trials were 13.3% [8] and 20% [7], and the failure to meet 
endpoints in a pembrolizumab Phase III clinical trial 
[9] together indicate the need for improved biomarkers 
to predict and monitor responsiveness to checkpoint 
inhibition.
Similar to approaches using targeted therapies, 
it is important to identify biomarkers of responses to 
checkpoint blockade therapy to determine whether the 
treatement is “on target”. However, detection of an 
activated, tumor-specific immune response has been 
limited by our ability to identify and characterize the anti-
tumor targets of the immune system. Recent work applying 
next generation sequencing to T cell antigen identification, 
termed “cancer immunogenomics”, has greatly facilitated 
the search for T cell specific targets recognized by the 
immune system [10–16]. In particular, the identification 
of “neoantigens” derived from tumor expressed mutations 
illustrates a functional genomics approach applied to 
anti-tumor immune recognition. Because the goal of this 
approach is to identify translated mutations predicted to 
bind with high affinity to MHC molecules, it emphasizes 
the antigenic potential of identified missense alterations 
instead of the classical “driver versus passenger” hierarchy 
of inferred biological function. The immunogenomics 
approach was first applied successfully in preclinical 
settings [14, 15] and has since been employed in expanded 
basic and translational contexts [17–19]. Importantly, 
neoantigen discovery may be particularly relevant in the 
identification of biomarkers of immunotherapy response 
and also as individual targets in personalized immune-
based treatments [20–22].
In HNSCC, there are several potential types of 
tumor antigens beyond mutation-derived neoantigens, 
including tumor-associated antigens, cancer-testis 
antigens, and viral antigens [23]. However, no studies to 
date have characterized the neoantigen burden of OSCC 
tumors or identified how anti-PD1 therapy influences 
the tumor infiltrating lymphocyte (TIL) population. To 
this end, we sought to identify and characterize tumor 
antigens in a preclinical carcinogen induced model 
of OSCC and investigate the association between 
infiltrating lymphocytes and checkpoint responsiveness. 
We previously described a syngeneic murine oral cavity 
squamous cell carcinoma (MOC) cell line model, 
including the indolent MOC22 and the aggressive MOC2 
[24], which displays high fidelity to human OSCC in 
biologic behavior and genomic landscape [25]. We first 
evaluated susceptibility of these models to treatment 
with anti-PD1 checkpoint blocking immunotherapy. To 
identify mutation-derived neoantigens in these tumors, we 
analyzed whole exome sequence data [25] of each tumor 
and applied multiple in silico prediction algorithms to 
identify potential H-2Kb and H-2Db restricted neoepitopes. 
Next, we confirmed the presence of antigen-specific 
T cells using IFNγ ELISPOT and dual-color tetramer 
analysis. Finally, we confirmed the therapeutic efficacy 
of neoantigen immunization in a prophylactic vaccine 
model. Thus, our proof-of-concept approach of neoantigen 
discovery and validation in preclinical OSCC contexts 
demonstrates the potential utility of this paradigm in 
human HNSCC.
RESULTS
Anti PD-1 checkpoint blockade responses
To identify an immunogenic preclinical model 
of OSCC, we investigated the response to checkpoint 
blockade of two syngeneic tumor cell lines — MOC2 
and MOC22 — which grow progressively in wild-type 
C57BL/6 mice. Anti-PD1 treatment of MOC22 tumors 
resulted in consistent rejection typically complete by day 
35 (Figure 1A). However, MOC2 tumors did not respond 
to anti-PD1 monotherapy (not shown) or to combination 
anti-PD1/anti-CTLA4 therapy and grew progressively 
with rapid growth kinetics (Figure 1B).
To determine whether the distinct response 
phenotypes of MOC22 and MOC2 correlated with 
differences in the immune microenvironment, we 
characterized the tumor immune infiltrate in the absence 
and presence of anti-PD1 treatment. Relative frequencies 
of intratumoral CD4+ and CD8+ T cells were analyzed with 
and without anti-PD1 treatment at 12 days post-transplant 
when tumors were at their largest size in MOC22 before 
the onset of rejection. With control antibody treatment, 
MOC22 tumors demonstrated significantly higher 
infiltrating CD8+ and CD4+ T cells compared to MOC2 
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tumors (p= 0.0013, p=0.0143, respectively). Whereas 
MOC22 harbored a significant increase in CD8+ T cell 
infiltration with anti-PD1 treatment (p=0.0195), no 
difference in the CD8+ T cell population was observed 
in MOC2 following checkpoint blockade treatment 
(p=0.2924) (Figure 1C). Notably, anti-PD1 treatment did 
not significantly alter CD4+ T cell infiltration in either 
tumor (MOC22 p= 0.2015, MOC2 p=0.1104).
Anti-PD1 induced transcriptome alterations in 
tumor and lymph node immune populations
To characterize transcriptomic alterations in tumor 
infiltrating hematopoietic cells due to checkpoint blockade 
by anti-PD1 in MOC22, we used a population RNA-Seq 
approach to interrogate the transcriptome in mice bearing 
day 17 tumors. We focused on this timepoint as day 17 
typically aligns with the onset of tumor rejection in the 
anti-PD1 treated cohort. We sorted CD45+ hematopoietic 
cells from non-hematopoietic CD45- cells and performed 
population RNA-Seq analysis in the CD45+ cells in control 
versus anti-PD1 mice bearing MOC22. Consistent with 
the FACS data in Figure 1 but distinct from the lymph 
nodes, CD8a transcripts were significantly increased in the 
tumor infiltrating immune cells. Other relevant transcripts 
that were significantly induced in the tumor CD45+ cells 
include Bhlhe40, Eomes S1PR1, TIM3 and CX3CR1.
We next interrogated immune cell populations 
in draining lymph nodes on days 11, 14 and 17 using a 
population RNA-Seq approach. These analyses revealed 
dramatic changes in the draining lymph node CD3+ T 
cell transcriptome with many immunologically relevant 
Figure 1: Responsiveness of (A) MOC22 to anti-PD1 and (B) MOC2 to combination anti-PD1/anti-CTLA4 therapy. Indicated 
tumor lines were injected at day 0, control or checkpoint targeting antibody therapy was administered on days 3, 6, and 9 and mice were 
monitored for tumor growth twice weekly. Filled circles are control treated and filled squares represent depleting antibody treated tumors. 
(C) Tumor infiltrating lymphocyte analysis of MOC2 and MOC22 treated with control or anti-PD1 blocking monoclonal antibodies. 
Tumors were harvested on day 12 post transplant from the indicated tumor bearing mice treated as in (A) and single cell suspensions were 
analyzed for CD8+ or CD4+ T cell infiltration normalized to CD45+ events (per 10,000 collected, *p<0.05).
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targets showing maximal expression at day 17 (Figure 
2B). Transcript families that were upregulated with anti-
PD1 treatment included transcription factors associated 
with activated CD4+ and CD8+ T cell responses (Id2, Id3, 
Tbx21, Tcf7, Myc, and others), cytokines and receptors 
involved in T cell proliferation, differentiation and 
cytolytic activity (IFNγ, TNF, IL7R, IL12Rβ2, Prf1 and 
GzmB) and surface receptors in lymphocyte migration, 
adhesion and immune checkpoints (CXCR3, CCR5, 
CXCR6, Sell, TIM3 and PD1) (Supplementary Figure 
1). Interestingly, we did not detect increased CD8 T 
cell transcripts in the lymph node. These transcriptomic 
changes were significantly increased in total CD3+ T cells 
in draining lymph nodes on day 17 compared to control 
antibody treated mice and showed progressive temporal 
induction/accumulation from day 11 to day 17. Although 
the overall pattern of increased induction of the distinct 
families was similar between the tumor milieu and 
draining lymph nodes, statistical significance was not 
achieved in several transcripts in the tumor (GzmB, IL7R, 
TNF, PRF1) and likely reflects the CD3+ T cell sort in the 
lymph node versus the total CD45+ hematopoietic sort in 
the tumor. Together these data show dramatic alterations in 
immune cell programs induced by anti-PD1 therapy.
In silico neoantigen prediction
To determine the potential antigen targets 
recognized in the checkpoint blockade setting [13], 
we characterized the mutation burden and subsequent 
neoantigen landscape of each tumor using an 
immunogenomics approach. As we have previously 
described [25], MOC22 has 3,111 nonsynonymous 
single nucleotide variants (nsSNVs) whereas MOC2 
Figure 2: Population RNA-Seq gene expression changes in MOC22 treated with anti-PD1 in tumor microenvironment 
and draining lymph node. MOC22 tumor bearing mice were treated as in 1A and TIL or draining lymph nodes were harvested at day 
17, sorted for CD45+ immune cells or CD3+ T cells, respectively, and subjected to RNA-Seq analysis. (A) Intratumoral anti-PD1 induced 
gene expression changes in D17 MOC22 CD45+ hematopoietic populations. Volcano plot on left with specific transcripts highlighted. The 
bar graph on right shows select relevant transcripts. (B) Volcano plot of gene expression changes in draining lymph node CD3+ T cells on 
day 17 post transplant. Highlighted are specific transcripts including IFNγ, TIM3, PD1, and CD8a. The bar graph on right shows select 
relevant transcripts (*=p<0.05, **p<0.01 and ***p<0.001).
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has only 534 (Figure 3A). We then applied an in silico 
bioinformatics pipeline to detect mutation-derived 
tumor neoantigens in which translated mutant peptides 
are prioritized based on the predicted affinity to bind to 
MHC class I in a similar manner as recent studies [13, 
16]. Using this approach, we assigned each predicted 
neoepitope a binding affinity score derived from the 
average scores of five prediction algorithms. Setting 
a cutoff of IC50 < 500 nM, MOC22 had 762 predicted 
neoantigens and MOC2 had 109. Applying an even 
stricter cutoff of 50 nM reduced predicted neoantigens 
to 50 for MOC22 and 7 for MOC2 (Figure 3B, 3C, 
Supplementary Tables 1 and 2). To further narrow the 
list of candidate antigens to only those present in the 
transcriptome, we then screened a more select list of even 
higher affinity candidates (IC50 <25nM) by targeted PCR 
and Sanger Sequencing to eliminate non-expressed gene 
products (data not shown). This approach revealed four 
high affinity candidates in MOC22 including mutated 
ICAM-1, H2-Q4, Chst15 and one candidate in MOC2, 
mutated Pkd1.
In vitro validation
Because MOC22 (1) displayed significant CD8+ 
T cell responses, (2) harbored an array of predicted 
neoantigen targets, and (3) exhibited robust therapeutic 
responses to anti-PD-1 therapy, we explored whether 
predicted neoantigen targets were indeed immunogenic. We 
performed IFNγ ELISPOT with isolated tumor infiltrating 
lymphocytes (TIL) from established subcutaneously 
implanted tumors. TIL isolated from MOC22 demonstrated 
increased activation following stimulation with the H-2Kb-
restricted ICAM1 P315L peptide (referred to as mICAM1; 
p= 0.0008; Figure 4A, 4B). This approach was attempted 
with MOC2 as well, but there were insufficient number of 
CD8+ T cells for ELISPOT (data not shown).
Following identification of mICAM1 as a 
neoantigen candidate for T cells infiltrating MOC22, we 
next examined whether we could detect antigen-specific 
T cells ex vivo from the growing tumor using tetramer 
analysis. TIL isolated from established MOC22 tumors 
were stained with mICAM1 or control tetramers and 
analyzed by flow cytometry (Figure 4C). Together, these 
data demonstrate that MOC22 tumors are infiltrated 
with T cells that recognize the tumor-derived mICAM1 
neoantigen.
Vaccination
Finally, to establish whether mICAM1 neoantigen-
specific T cells alone can induce tumor rejection of 
mICAM1-expressing MOC22 cells, we tested the 
hypothesis that prophylactic vaccination with mICAM1 
peptides would protect mice from the growth of MOC22 
in the absence of checkpoint blockade immunotherapy 
(Figure 5A). To establish the efficacy of our vaccination 
modality to induce mICAM-specific immune responses, 
mice were immunized mice with two doses of a 28 amino 
acid synthetic long peptide (SLP) containing the mICAM1 
neoantigen together with adjuvant PolyIC:LC. Splenocytes 
from immunized mice demonstrated significant IFNγ 
stimulation when cultured with mICAM-1 peptide but 
not control peptides, demonstrating the immunogenicity 
of the mICAM-1 SLP. Having established that mICAM-1 
SLP plus PolyIC:LC produces antigen specific immunity, 
we tested the capacity of mICAM-1 vaccination to 
prevent MOC22 tumor growth by vaccinating mice twice 
within 1 week prior to tumor implantation (Figure 5B). 
In mice vaccinated with control poly-ICLC, all MOC22 
bearing mice displayed progressively growing tumors. 
Mutant ICAM1 vaccination did not protect mice from 
challenge with the unrelated MOC2 tumor cell line. 
However, MOC22 tumors were rejected in 80% of the 
Figure 3: (A) Mutation burden of MOC22 and MOC2 and predicted neoantigen burden (IC50<50nM) in each tumor. (B, C) 
Manhattan plot of affinity score (1/IC50)
*100 of top candidate neoantigens in MOC2 and MOC22. Labeled are the selected highest predicted 
binding affinity candidate neoantigens in each tumor cell line.
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mice vaccinated with mICAM1 (Figure 5C). Together, 
these data show that mICAM1-specific immunity 
alone can induce the rejection of mICAM-1-expressing 
MOC22 tumors and validate that mICAM-1 is a bona fide 
neoantigen capable of tumor protection.
DISCUSSION
Immunogenomic approaches have dramatically 
advanced our capacity for neoantigen identification and 
defined their role as key targets of immunotherapies, as 
biomarkers of response and, as confirmed in recent studies, 
their potential as vaccines [26–28]. In addition, several 
recent studies identified that checkpoint inhibitor-induced 
tumor rejection is mediated by neoantigen-specific T cells 
[12, 13]. As carcinogen induced OSCCs have a significant 
mutation burden, a finding correlated with increased 
neoantigen loads, this tumor type represents an ideal 
immunotherapy target. Despite this potential, Phase III 
data in recurrent, and/or metastatic head and neck cancers 
shows low response rates with nivolumab and a failure 
to meet survival endpoints with pembrolizumab. Thus, 
there is a pressing need to identify OSCC model systems 
with defined immunobiology in order to better leverage 
Figure 4: Detection of neoantigen-specific TIL. (A) Representative images of the IFNγ ELISPOT plate demonstrating TIL reactivity 
to mICAM1 but not other predicted neoantigens (control including Chst15 and H2-Q4). Tumor infiltrating lymphocytes were isolated from 
growing MOC22 tumors on day 12, expanded in IL2 media (100U/mL in R10), and plated overnight with 25,000 TIL, 100,000 radiated 
APCs, and 1μM peptide per well. IFNγ production was assessed the following day by ELISPOT. (B) Bar graph quantifying results of IFNγ 
ELISPOT (**p<0.01). (C) Detection of mutant ICAM1 neoantigen-specific intratumoral CD8+ T cells by dual-labeled tetramer staining. 
Left panel shows control tetramer with wild type peptide sequence and right panel is with mICAM1 peptide.
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immunotherapeutic modalities in this disease setting. To 
define a robust pre-clinical system for studying immune 
based treatments in OSCC, we first delineated checkpoint 
responses in our syngeneic model system and identified 
both responsive (MOC22) and resistant (MOC2) models. 
Transcriptomic approaches provided a window into the 
temporal and spatial (primary tumor versus lymph node) 
gene expression changes induced by anti-PD1 blockade in 
MOC22. We then applied an immunogenomics pipeline and 
defined the mICAM1 epitope as a neoantigen in MOC22 
and demonstrated the potential for personalized antigen 
specific vaccination in mice bearing this tumor. Thus, these 
data identify a robust pre-clinical platform with defined 
responses and biology for further investigating checkpoint 
and neoantigen specific OSCC studies.
Immunogenomics based approaches were first 
defined in mouse sarcoma and melanoma models and 
have since been extended to brain tumors [29]. Broadly 
speaking, there are manifold applications of neoantigen 
discovery in cancer—as targets, as biomarkers, and 
as probes to study the basic immunobiology of T cell 
responses to endogenous tumor antigens [23]. We 
anticipate that these approaches will all be highly germane 
to head and neck cancer. Our work here represents the 
first study to define both checkpoint and neoantigen 
specific responses in an OSCC model. Specifically, 
the immunogenic mICAM neoantigen was detected 
in both spontaneous immune responses and also was 
a therapeutically relevant vaccine target in protective 
settings. Ongoing work in our OSCC models is directed at 
elucidating the most effective methodologies to vaccinate 
in therapeutic settings and at investigating combination 
approaches in the MOC2 tumor that is persistently 
unresponsive to immunotherapies.
The MOC models were generated in order to 
establish syngeneic carcinogen induced platforms to 
investigate host responses to OSCC tumor challenge. Our 
work highlights key biological observations that need to 
be clarified at a more granular level. First, our early work 
established the aggressive biology of the MOC2 tumor and 
identified it as a T cell “non-inflamed” model [30]. Here, 
we confirmed these findings and extended data to show 
that MOC22 contains significant numbers of intratumoral 
CD8+ T cells. Similar to findings in anti-PD1 treated 
melanoma samples, anti-PD1 treated MOC22 displayed 
an increase in intratumoral CD8+ T cells [31]. There are 
multiple mechanisms which may contribute to the lack of 
response to anti-PD1 in MOC2 and these include in part, a 
lack of high affinity neoantigens and a limited CD8+ T cell 
infiltrate. Ongoing work will be directed at understanding 
the basis for the poor immunogenicity seen in the MOC2 
system.
Second, deep transcriptomic analysis showed 
significant alterations in global effector/memory, 
chemotactic and checkpoint programs. Previous analyses 
of transcriptomic data from antigen specific T cells in 
a checkpoint responsive murine sarcoma model have 
defined alterations in metabolic, signaling and T cell 
effector pathways after treatment with anti-PD1, anti-
CTLA-4 or combination therapy [13]. More recently, 
transcriptomic comparison of CD4+ T cells at baseline and 
antigen specific CD4+ T cells after neoantigen vaccination 
in melanoma patients revealed significant induction of 
effector and memory T cell gene expression programs 
including Tbx21 [26]. Herein, we also observed Tbx21 
induction in the lymph node CD3+ T cell compartment 
in addition to other effector and memory programs. 
Importantly, our analysis defines a temporal progression 
Figure 5: Preventative mICAM1 synthetic long peptide (SLP) vaccination. (A) Validation of mICAM1 SLP vaccine to 
generate mICAM1-specific T cell responses. Mice were immunized with mICAM1 SLP or control polyIC:LC alone and spleens were 
harvested 7 days post-vaccination. Splenocytes (100,000 cells/well) were plated with 1μM short peptide and evaluated for IFNγ production 
by ELISPOT (T/I is control with TPA and ionomycin stimulation). (B) Prophylactic vaccination study design with immunization on days 
-7 and -5 followed by tumor challenge on day 0. (C) Kaplan-Meier survival curve for mICAM1 preventative vaccination. Mice were 
immunized with PolyIC alone or in combination with mICAM1 SLP and challenged with MOC2 (solid line with mICAM1 vaccine) or 
MOC22 (dashed line polyIC:LC control or dotted line with mICAM1). This is representative of two independent experiments with the same 
MOC22 result (n=4 mice for each group).
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of these changes with maximal induction values for many 
programs at the day 17 time point within the lymph node. 
Future work will address the evolution of these changes 
in gene expression modules both temporally and also 
spatially with respect to distinct anatomic regions of the 
tumor and secondary lymph node sites.
The promise of personalized neoantigen vaccine 
approaches is at an early stage with exciting early trial 
data in melanoma patients [28, 32]. Our definition of 
the mutant ICAM1 neoantigen for MOC22 will allow 
OSCC specific studies. Our current neoantigen biomarker 
work is aimed at defining mICAM1 specific responses 
in other immunotherapeutic approaches and in defining 
optimal therapeutic vaccination schema including rational 
combination strategies in established tumor settings.
MATERIALS AND METHODS
Mice
C57BL/6 mice were purchased from Taconic. All in 
vivo experiments used 8-12 week old female mice housed in 
a pathogen-free animal facility and all experiments performed 
were approved by the AAALAC accredited Animal Studies 
committee of Washington University in St. Louis.
Tumor transplantation
MOC cell lines were generated, characterized 
and propagated as previously described [24]. MOC cell 
lines were cultured in IMDM/Hams-F12 with 5% FCS. 
For transplantation, cells were washed extensively and 
resuspended in endotoxin-free PBS (Fisher) and injected 
subcutaneously into the flanks of mice. Tumor growth was 
monitored biweekly and tumor volume was calculated 
based on the formula (L X W2)/2.
Checkpoint blockade experiments
MOC2 and MOC22 cell lines were transplanted into 
the subcutaneous flank of mice as above. Mice were treated 
with intraperitoneal injection of anti-PD1 (Clone RMP1-
14, Leinco, 250 micrograms) or control antibody (anti-2a3, 
Leinco, 250 micrograms) on days 3, 6, 9 after transplant. 
Tumor growth was monitored as above and comparison of 
the two cohorts was made using two-way ANOVA.
TIL analysis
MOC22 tumor bearing mice were treated with 
control or anti-PD1 antibody as above. Day 12 tumors 
were harvested and processed into single cell suspensions. 
Cells were stained with Zombie NIR (live/dead cells, 
BioLegend), CD45 (PerCP-Cy5.5, BioLegend), CD3 
(FITC, BioLegend), CD4 (APC, BioLegend), and CD8 (PE, 
BioLegend) and analyzed on a Fortessa Flow Cytometer. 
Comparison groups were compared using Student’s t-test.
Population RNA-Seq analysis
MOC22 tumor bearing mice were treated with 
control or anti-PD1 antibody as above. Draining lymph 
nodes (days 11, 14 and 17) or tumor (day 17) were 
harvested. Single cell suspensions of lymph node 
cells gated on CD3+ or CD3- populations were then 
FACS sorted, immediately spun down and stored in 
TCL buffer (Qiagen) snap frozen at -80 C. Tumor cell 
suspensions were similarly sorted into live CD45+ or 
CD45- cell populations. Samples were processed using 
SmartSeq 2 protocol (Clontech, Mountain View, CA) 
with modifications [33]. cDNA generated with Smartseq 
2 protocol was converted to Illumina seq libraries using 
Nextera (Illumina, San Diego, CA). Samples were 
sequenced on Illumina Nextseq. RNA-Seq reads were 
aligned to the mouse reference genome with Bowtie 2 
[34]. Expression levels were quantified in TPM using 
RSEM [35]. Differential expression was computed using 
t test after log transformation of expression data. The 
multiple hypothesis testing correction was computed with 
Benjamini-Hochberg method [36].
Neoepitope prediction
Nonsynonymous coding variants for MOC2 and 
MOC22 [25] were analyzed for potential binding to MHC 
class I H-2Kb or H-2Db molecules using the Stabilized Matrix 
Method (SSM) algorithm, the Artificial Neural Network 
(ANN) algorithm, and the NetMHCpan algorithm provided 
by the Immune Epitope Database and Analysis Resource 
(http://www.immuneepitope.org) [37–39]. These analyses 
were used to predict epitope processing and binding affinity 
and the results are expressed as an affinity value combined 
with 1/IC50 where IC50 is the half-maximum inhibitory 
concentration as has been previously reported [13].
ELISPOT
Day 12 tumors were resected and cultured in IL-2 
(100U/mL) to expand the tumor infiltrating lymphocytes 
(TIL). After 48 hours, TIL were harvested and selected 
for live cells (Miltenyi) and incubated at 1.5 x 105 cells 
with 2.5x105 naïve splenocytes and 1uM peptide (Peptide 
2.0) in an ELISPOT plate pre-coated with anti-interferon-γ 
antibody (Immunospot). ELISPOT was performed per 
manufacturer’s direction and plates were read in the 
Immune Monitoring Lab (IML) of the Center for Human 
Immunology and Immunotherapy Programs (CHIIPS) at 
Washington University.
Tetramer staining
Tetramer reagents were produced in the IML of CHIIPS 
at Washington University. Briefly, recombinant H-2Kb and 
β2-microglobulin were produced in BL21-CodonPlus (DE3)-
RIPL Escherichia coli (Agilent) and purified from inclusion 
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bodies by size-exclusion FPLC as previously described [40]. 
UV-mediated exchange of candidate epitopes generated 
peptide-specific monomers which were multimerized by 
streptavidin-conjugated PE or APC as previously described 
[35]. TIL were stained with peptide-MHC I tetramers for 15 
minutes at 37°C and then with CD8α-FITC, CD45-PerCP-
Cy5.5, and Zombie NIR Fixable Viability Kit and analyzed 
on a BD Fortessa Flow Cytometer.
Synthetic long peptide (SLP) vaccination
Immunizations were performed by injecting 
mICAM1 synthetic long peptide (DQILETQRTLTVYN 
FSALVLTLSQLEVS, 50 micrograms, Peptide 2.0) with 
PolyIC:LC (Invivogen, 100 micrograms) or PolyIC:LC 
alone into the subcutaneous flank on days -7 and -5 and 
tumor challenge was performed on day 0. Tumor growth 
was monitored as above.
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